PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan Noriomi MatsumuraMasaki Mandai PMDA Regulatory Update 29 March 2024
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay Tadayoshi HashimotoYoshiaki NakamuraTakayuki Yoshino JSCO Board of Directors Series Open access 29 March 2024
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022 Shoji KimuraKeisuke ShigetaYuji Miura Special Article 28 March 2024
MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial Han Byul KangSung Hwan KimJong Hoon Lee Original Article 26 March 2024
PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site João Neif Antonio JuniorDaniel D.’Almeida PretoFlavio Mavignier Cárcano Original Article Open access 25 March 2024